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Myocardial Tissue Remodeling in Adolescent Obesity
Ravi V. Shah, MD;* Siddique A. Abbasi, MD;* Tomas G. Neilan, MD; Edward Hulten, MD, MPH; Otavio Coelho-Filho, MD, MPH;
Alison Hoppin, MD; Lynne Levitsky, MD; Sarah de Ferranti, MD, MPH; Erinn T. Rhodes, MD, MPH; Avram Traum, MD;
Elizabeth Goodman, MD; Henry Feng, BS; Bobak Heydari, MD; William S. Harris, PhD; Daniel M. Hoefner, PhD;
Joseph P. McConnell, PhD; Ravi Seethamraju, PhD; Carsten Rickers, MD; Raymond Y. Kwong, MD, MPH; Michael Jerosch-Herold, PhD
Background-—Childhood obesity is a signiﬁcant risk factor for cardiovascular disease in adulthood. Although ventricular
remodeling has been reported in obese youth, early tissue-level markers within the myocardium that precede organ-level
alterations have not been described.
Methods and Results-—We studied 21 obese adolescents (mean age, 17.72.6 years; mean body mass index [BMI], 41.99.5 kg/
m2, including 11 patients with type 2 diabetes [T2D]) and 12 healthy volunteers (age, 15.14.5 years; BMI, 20.13.5 kg/m2) using
biomarkers of cardiometabolic risk and cardiac magnetic resonance imaging (CMR) to phenotype cardiac structure, function, and
interstitial matrix remodeling by standard techniques. Although left ventricular ejection fraction and left atrial volumes were similar in
healthy volunteers and obese patients (and within normal body size-adjusted limits), interstitial matrix expansion by CMR extracellular
volume fraction (ECV)was signiﬁcantly different between healthy volunteers (median, 0.264; interquartile range [IQR], 0.253 to 0.271),
obese adolescents without T2D (median, 0.328; IQR, 0.278 to 0.345), and obese adolescents with T2D (median, 0.376; IQR, 0.336 to
0.407; P=0.0001). ECV was associated with BMI for the entire population (r=0.58, P<0.001) and with high-sensitivity C-reactive
protein (r=0.47, P<0.05), serum triglycerides (r=0.51, P<0.05), and hemoglobin A1c (r=0.76, P<0.0001) in the obese stratum.
Conclusions-—Obese adolescents (particularly those with T2D) have subclinical alterations in myocardial tissue architecture
associated with inﬂammation and insulin resistance. These alterations precede signiﬁcant left ventricular hypertrophy or decreased
cardiac function. ( J Am Heart Assoc. 2013;2:e000279 doi: 10.1161/JAHA.113.000279)
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O ver the last decade, adolescent obesity has taken onepidemic proportions, with nearly 17% of children aged 2 to 19 years classiﬁed as obese.
1 Childhood obesity is
strongly associated with future cardiovascular risk,2 with
elevated body mass index (BMI) and type 2 diabetes in
adolescence associated with metabolic syndrome,3,4 and with
reduced survival in adulthood.5 Obese children exhibit a
cardiometabolic phenotype similar to that seen in adult
metabolic syndrome, including left ventricular hypertrophy
(LVH), diastolic dysfunction, and increased vascular stiff-
ness,6,7 precursors of future heart failure. These structural
and functional changes likely represent an advanced, estab-
lished stage of disease, in which adverse prognosis and
permanent alterations may not be amenable to reversal.
Indeed, data from animal models of obesity suggest that early,
subtle cardiomyocyte hypertrophy and interstitial matrix
expansion (with collagen or advanced glycation end products)
may predate organ-level pathology.8–11 Novel noninvasive
imaging techniques to address myocardial tissue-level phe-
notypes would afford unique insights into myocardial tissue
remodeling not easily accessible by traditional cardiac
imaging.
Recently, our group and others have developed and
histologically validated T1-based cardiac magnetic reso-
nance imaging (CMR) techniques to quantify myocardial
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interstitial matrix expansion (extracellular volume fraction
[ECV]).12,13 Postcontrast myocardial T1 is abnormal in
adults with diabetes, and correlates with the degree of
diastolic dysfunction, inﬂammation, and insulin resis-
tance.14,15 However, whether these preclinical alterations in
myocardial tissue structure exist earlier in the life course of
diabetic heart disease (eg, obese pediatric subjects) remains
unknown.
To investigate whether obesity is associated with such
abnormalities in a pediatric population, we compared cardiac
structural, functional, and tissue phenotypes in obese
adolescents with and without type 2 diabetes (T2D) with
those in normal-weight, healthy volunteers. We speciﬁcally
hypothesized that measurements of interstitial matrix expan-
sion would be abnormal in obese adolescents, speciﬁcally
those with T2D. We also hypothesized that adverse tissue
remodeling would be associated with circulating biomarkers
of inﬂammation and insulin resistance, postulated to play
central roles in cardiometabolic pathways implicated in
subclinical myocardial tissue remodeling.
Methods
Study Population
We prospectively enrolled 21 obese adolescents (age, 15 to
19) from the Massachusetts General Hospital for Children
(Boston, MA) and the Boston Children’s Hospital (Boston,
MA). Obesity was deﬁned by BMI ≥30 kg/m2 or ≥95th
percentile for age and sex.16 Patients with a history of
hypertension and type 2 diabetes (based on American
Diabetes Association criteria17) were included in the study,
given their association with adolescent obesity. We excluded
patients with (1) contraindications to MRI (eg, metallic
hazards or allergy to gadolinium), (2) prior bariatric surgery,
(3) creatinine clearance ≤30 mL/min, (4) active pregnancy,
(5) body weight >250 kg or waist size >70 cm (limits for our
cardiac MRI system), and (6) prior heart disease (eg,
repaired/unrepaired congenital, cardiomyopathy, myocardial
infarction). We selected adolescents who were postpubertal
to limit the effects of physiologic insulin resistance of
puberty. Before CMR imaging, patient height, weight, systolic
and diastolic blood pressure, and heart rate were collected. A
group of 12 healthy, normal-weight adolescent and young
adult volunteers free of any cardiovascular risk factors or
clinical disease were collected from Kiel, Germany, and
Boston, Massachusetts, and imaged using similar protocols
for comparison (age, 15.14.5). The institutional review
boards of each participating institution approved the study
protocol, and all subjects and their parents or guardians (for
age <18 years) gave assent and/or informed consent for the
study.
CMR Protocol and Analysis
For obese adolescents, CMR imaging was performed on a
3.0-Tesla scanner (16-element coil, 70-cm bore size; Siemens
Verio, Siemens, Erlangen, Germany) with vector-cardiographic
gating. No premedication was used. For healthy volunteers, a
3.0-Tesla scanner (Achieva 3.0T, Philips Medical Systems, the
Netherlands) was used with a phased-array coil for cardiac
imaging. In patients younger than 7 years old, sedation with
propofol and midazolam was necessary. Cine steady-state
free precession (SSFP) was performed for a stack of short-axis
slices to cover the left and right ventricles (25 phases; TR/
TE/ﬂip angle=3.2 ms/1.8 ms/45°; slice thickness=6 mm;
1929170 matrix; FOV 3409320 mm; iPAT=2; temporal
resolution=35 to 50 ms) and in radial views for left atrial
volume assessment.18 Single-shot SSFP late-enhancement
imaging in the short-axis orientation with full ventricular
coverage was performed 10 minutes after administration of
0.15 mmol/kg intravenous gadolinium-DPTA (Magnevist; Ba-
yer Healthcare, Wayne, NJ). To assess thoracic aortic arterial
stiffness, we measured aortic pulse wave velocity (PWV) via
free-breathing phase-contrast imaging (gradient echo acqui-
sition; rectangular FOV=27932 cm; 1929162 matrix; effec-
tive temporal resolution ≤12.5 ms; 80 phases per R-to-R
interval; 3 averages; retrospective ECG gating) of an axial slice
intersecting the ascending and descending aorta at the right
pulmonary artery level. The distance between the ascending
and descending aortic axial slices (for calculation of PWV) was
measured on a separate candy-cane aortic image. All images
acquired with breath holding were timed to end-expiration.
CMR images are analyzed off-line using specialized post-
processing software (MASS, Medis Research, Leiden, the
Netherlands). Standard modiﬁed Simpson’s methods were
used to analyze left ventricular (LV) and right ventricular
volumes, mass, and function. Left atrial volumes and function
(markers of diastolic dysfunction) were assessed from radial
cine views of the left ventricle as described.18 Flow-versus-time
curves from locations in the ascending and descending thoracic
aorta were obtained from phase-contrast images and analyzed
by the cross-correlation method to determine pulse wave
delays. Ventricular volumes and mass were indexed to height.
CMR T1 Measurements
T1 measurements were performed once precontrast and 4
times postcontrast with a breath-hold Look-Locker tech-
nique.19,20 The segmented gradient-echo sequence had a
temporal resolution of 117 ms for precontrast T1 measure-
ments and 55 ms for postcontrast T1 measurements and
included a non-slice-selective BIR-4 adiabatic inversion pulse
applied after the detection of an R-wave, followed by a
acquisition of segmented k-space data for 17 cardiac phases,
DOI: 10.1161/JAHA.113.000279 Journal of the American Heart Association 2
Myocardial Tissue Remodeling in Adolescent Obesity Shah et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
that is, times after inversion (TR/TE/ﬂip angle=5 ms/
2.2 ms/10°; slice thickness=8 mm; 1929100 matrix; FOV
340930 to 340 mm; NEX=1; IPAT=2). The ﬂip angle was
low (10°) to maintain high sensitivity to T1 changes. The
sequence was validated against inversion-recovery-prepared
spin-echo measurements, as described previously.21 For
healthy volunteers, an identical sequence was used with a
temporal resolution of 90 ms precontrast, and 40 ms post-
contrast. T1 measurements were made in a single mid–left
ventricular slice. Postcontrast T1 measurements started
5 minutes after the injection of gadolinium contrast, with 4
subsequent T1 measurements performed over a period of
30 minutes postcontrast. Endocardial and epicardial contours
were drawn in a midventricular slice, taking care to avoid
blood pool, using dedicated software (MASS). A region of
interest was also placed in the blood pool. The left ventricle
was segmented into 6 sectors for analysis. Segmental T1 was
derived by exponential ﬁtting of the inversion recovery and
correction for radio-frequency pulse effects. Segmental
myocardial R1 (=1/T1) was plotted against blood R1. We
subsequently ﬁtted the data for R1 for each myocardial
segment as a function of R1 in blood with a 2-space
water-exchange model of equilibrium transcytolemmal water
exchange, originally developed by Landis et al,22 with the
slope of the initially linear relation deﬁning a partition
coefﬁcient for gadolinium, kGd, for each segment. Myocardial
ECV for each segment was calculated by multiplying kGd by
(1hematocrit), and then the 6 myocardial segments were
averaged for a ﬁnal myocardial ECV. We have established that
this technique demonstrates a high degree of reliability, with a
meanstandard deviation of the test–retest difference of
0.000.012 (95% CI, 0.015 to 0.015) over a period of 1
month, with an intraclass correlation coefﬁcient of 0.902.
Biomarker Collection
Blood was collected in a fasting state for assessment of
selected biomarkers of inﬂammation, adiposity, and insulin
resistance. A lipid panel was obtained clinically in all obese
patients. We assayed markers of systemic inﬂammation
(eg, high-sensitivity C-reactive protein, triglycerides), insulin
resistance (insulin, homeostatic model assessment of insulin
resistance [HOMA-IR], hemoglobin A1c), adiponectin, and
leptin. In addition, we assayed cardiac-speciﬁc markers of
hemodynamic stress and ﬁbrosis (N-terminal pro-BNP, galec-
tin-3). Biomarkers were collected in fasting conditions at the
time of CMR. Hemoglobin A1c was obtained via review of
medical records (median time between hemoglobin A1c and
CMR, 101 days; IQR, 51 to 219 days). HOMA-IR was
calculated as fasting insulin (in lU/mL)9fasting glucose (in
mg/dL)/405.23 Biomarker assessment was not performed on
healthy volunteers in our control population.
Lipid panel analyses (total cholesterol, triglyceride,
low-density lipoprotein cholesterol, and high-density lipopro-
tein cholesterol) were performed using direct, automated,
enzymatic, colorimetric methods on a Roche P-Modular
system (Roche Diagnostics, Indianapolis, IN). High-sensitivity
C-reactive protein was measured using an immunoturbidimet-
ric method on a Roche P-Modular system. Insulin and
NT-proBNP were measured by the electrochemiluminescent
immunoassay using Roche reagents on a Roche Modular E170
system. Adiponectin was measured using a latex particle–
enhanced immunoturbidimetric assay from MedTestDx (Arling-
ton, VA) on a Roche P-Modular system. Leptin was analyzed
using an enzyme-linked immunosorbant assay (ELISA) from
Mercodia, (Uppsala, Sweden) on a DSX automated immuno-
assay analyzer from Inova diagnostics (San Diego, CA).
Galectin-3 was measured using a microtiter plate-based
ELISA method form BG Medicine (Waltham, MA).
Statistical Analysis
We powered the study on the basis of preliminary data
in healthy adult volunteers (<40 years; mean ECV,
0.2520.016). In the absence of previous data on the effect
of obesity on ECV, we aimed to detect a difference in means
of 0.024 units, which corresponds to the difference in ECV
between its mean and 95th percentile in normal healthy
volunteers.24 With a standard deviation of 0.016, as observed
for ECV in volunteers, the assumed effect size is 1.5. This
could be deemed a minimal, clinically signiﬁcant change in
ECV. With an effect size of 1.5, the analysis of 21 patients
gives >90% power to detect this difference with a type 1 error
probability of 0.01. Baseline clinical and CMR characteristics
were compared by the Wilcoxon rank-sum test (for continuous
covariates) and the Fisher exact test (for categorical covari-
ates). For the purpose of identifying the association between
obesity and tissue remodeling (myocardial ECV), we per-
formed nonparametric Kruskal–Wallis testing across multiple
groups (healthy volunteers, obese adolescents without T2D,
obese adolescents with T2D), with adjustment of the P values
from pairwise post hoc comparisons (Wilcoxon) by the
Hochberg method. To clarify possible mechanistic relation-
ships between inﬂammation and insulin resistance with
myocardial tissue phenotypes, we measured Spearman
rank-order correlation coefﬁcients between serum biomarkers
and myocardial ECV.
Results
Patient Characteristics
Baseline characteristics of patients stratiﬁed by obesity and
diabetic status (as deﬁned above) are summarized in Table 1.
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The mean body mass index was 20.13.5 kg/m2 in healthy
volunteers, 41.46.0 kg/m2 in adolescents with obesity
alone, and 42.412.1 kg/m2 in adolescents with obesity and
diabetes (P<0.0001). The age and sex distributions were
similar in all 3 groups. However, obese individuals had a
higher median systolic blood pressure (139 mm Hg) than
obese diabetics (127 mm Hg), and healthy volunteers
(108 mm Hg); Kruskal–Wallis P=0.0005 between all 3 groups.
Of the 11 diabetic adolescents, 5 (45%) were on insulin
therapy (versus none of the obese nondiabetic patients;
P=0.04). Nine of the 11 obese diabetic adolescents (82%)
used oral antihyperglycemic therapy (versus 1 nondiabetic;
P=0.002). Obese adolescents (particularly those with T2D)
had an adverse cardiometabolic and inﬂammatory proﬁle
(Table 2), with abnormalities in high-sensitivity C-reactive
protein, proatherogenic dyslipidemia, and markers of insulin
resistance, dysglycemia, and adiposity. When comparing
obese individuals with and without diabetes, there were no
Table 1. Baseline Characteristics Stratiﬁed by Obesity and Diabetic Status
Variable
Healthy
Volunteers
(n=12)
Obesity
Alone
(n=10)
Obesity+T2D
(n=11)
P Value
All Patients
P Value
Obesity+T2D vs
Obesity Alone
Clinical characteristics
Age, y 15.14.5 18.13.6 17.41.4 0.2 0.7
Female, n (%) 5 (42) 5 (50) 7 (64) 0.6 0.7
Weight, kg 53.615.4 12018.7 12229.8 <0.0001 0.9
Body mass index, kg/m2 20.13.49 41.45.99 42.412.1 <0.0001 0.8
Body surface area, m2 1.560.31 2.280.199 2.210.282 <0.0001 0.7
Systolic blood pressure, mm Hg 108 [97.8 to 110] 139 [120 to 150] 127 [117 to 136] 0.0005 0.003
Hypertension, % 0 (0%) 3 (30%) 3 (27%) 0.09 1
CMR characteristics
LV end-diastolic volume
(indexed), mL/m
77.4 [67.4 to 84.8] 111 [93.7 to 117] 87 [81 to 111] 0.004 0.001
LV end-systolic volume
(indexed), mL/m
30.3 [26.5 to 35.3] 41.6 [36.7 to 50.2] 34.8 [32.5 to 38.6] 0.01 0.01
LV ejection fraction, % 58.7 [56.4 to 60] 58.7 [57.1 to 60.9] 58.8 [58.2 to 61.5] 0.7 0.8
LV mass (indexed), g/m 46.9 [38.6 to 53.3] 74.6 [64.5 to 80.5] 66.7 [55.4 to 69.7] 0.001 0.0006
LV mass-to-volume ratio 0.59 [0.537 to 0.711] 0.689 [0.658 to 0.723] 0.604 [0.559 to 0.769] 0.3 0.4
RV end-diastolic volume
(indexed), mL/m
76.9 [71 to 80.4] 97 [94.1 to 106] 91 [76.1 to 98.5] 0.04 0.02
RV end-systolic volume
(indexed), mL/m
37.8 [36 to 41.7] 48.2 [43.2 to 50.7] 43.4 [34.6 to 48.6] 0.1 0.09
RV ejection fraction, % 49 [46.4 to 52] 49.4 [47.5 to 51.8] 51.4 [48.6 to 56.7] 0.5 0.8
Maximum left atrial volume, mL 45.7 [38.3 to 51.6] 54 [44.4 to 70.9] 51 [44.5 to 66.8] 0.4 0.9
Myocardial extracellular volume 0.264 [0.253 to 0.271] 0.328 [0.278 to 0.345] 0.376 [0.336 to 0.407] 0.0001 0.03
Aortic pulse wave velocity, m/s 3.4 [3.21 to 3.58] 3.01 [2.87 to 3.07] 3.23 [3.06 to 3.86] 0.1 0.2
Biomarkers
Glucose, mg/dL — 83 [83 to 88] 122 [94 to 312] 0.01 0.01
Hemoglobin A1c, % — 5.55 [5.30 to 5.60] 8.0 [6.70 to 10.75] 0.0004 0.0005
HOMA-IR — 3.2 [2.5 to 6.8] 7.7 [3.85 to 15.5] 0.1 0.1
Triglycerides, mg/dL — 96 [80 to 106] 206 [104 to 322] 0.02 0.02
High-sensitivity CRP, mg/L — 1.7 [1.1 to 6.0] 8.25 [4.47 to 10.5] 0.09 0.1
Galectin-3, ng/mL — 11.8 [11.0 to 14.6] 15.5 [14 to 16] 0.04 0.05
Adiponectin, lg/mL — 8 [8 to 9] 5.5 [4.25 to 7.75] 0.03 0.03
All volumes are indexed to height. Values are expressed as meanstandard deviation, or median and interquartile range (in brackets) depending on data normality. T2D indicates type 2
diabetes; CMR, cardiac magnetic resonance imaging; LV, left ventricular; RV, right ventricular; HOMA-IR, homeostatic model assessment of insulin resistance; CRP, C-reactive protein.
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signiﬁcant differences in BMI (Table 1). Obese individuals with
T2D had a higher fasting glucose (P=0.0098), a higher serum
triglyceride level (P=0.022), a higher galectin-3 level
(P=0.042), and a lower adiponectin level (P=0.027) compared
with obese adolescents without T2D.
Standard Markers of Cardiac Structure and
Function by CMR
Left and right ventricular function was similar in healthy
volunteers and obese patients (Table 1, Figure 1). Left
ventricular ejection fraction (LVEF) was indistinguishable
between the healthy volunteers (58.7%), obese adolescents
without T2D (58.7%), and obese adolescents with T2D
(58.8%); P=0.74. When indexed to height, the left ventricular
end-diastolic volume (LVEDVI) was larger in adolescents with
obesity alone (111 mL/m) than in adolescents with obesity
and T2D (87 mL/m) or healthy volunteers (77.4 mL/m);
P=0.004. Height-indexed left ventricular mass was also larger
in obese adolescents (74.6 g/m) compared with obese
adolescents with T2D (66.7 g/m) and healthy volunteers
(46.9 g/m); P=0.001. Based on threshold echocardiographic
values (>95th percentile of normal) to deﬁne LVH in children
and adolescents (male LV mass >99.8 g/m, female LV
mass >81.0 g/m),25 only 1 female (81.9 g/m) and 1 male
(103 g/m) had indexed LV mass barely higher than the
threshold value. Given differences in systolic blood pressure
among the groups and potential confounding by degree of
hypertension, we adjusted volumes and mass by systolic
blood pressure to compare LV parameters between groups.
With adjustment for systolic blood pressure, left ventricular
volumes did not differ among the 3 groups. Height-indexed
left ventricular mass corrected for systolic blood pressure was
highest in the group with obesity alone. Left ventricular
mass-to-volume ratio (a marker of concentric LV remodeling)
among the 3 groups was not signiﬁcantly different with and
without simultaneous adjustment by blood pressure. Finally,
left atrial volume and aortic pulse wave velocity (markers of
left atrial pressure overload and vascular stiffness in obese
cardiovascular remodeling, respectively) did not signiﬁcantly
differ among healthy volunteers, obese adolescents with T2D,
and obese adolescents without T2D.
Myocardial Tissue Remodeling in Pediatric
Obesity
Myocardial ECV differed signiﬁcantly by obesity and diabetic
status. Median myocardial ECV was 0.264 (0.253 to 0.271) in
healthy volunteers versus 0.328 (0.278 to 0.345) in obese
adolescents without T2D. Obese adolescents with T2D had the
highest degree of interstitial matrix expansion, at 0.376 (0.336
to 0.407; Figure 2A). Of note, ECV was still higher in the obese
with and without T2D after adjustment by systolic blood
pressure in linear regression models adjusted for blood
pressure. Myocardial ECV was signiﬁcantly associated with
body mass index in the entire population (r=0.58, P<0.001;
Figure 2B). A higher myocardial ECV was also associated with
smaller height-indexed LV end-systolic volume index (in obese,
r=-0.46, P=0.03) and higher LVEF (in obese, r=0.45, P=0.04),
but not with height-indexed LV mass, LV mass-to-volume ratio,
aortic pulse wave velocity, or LA volumes in the obese and in
the overall pooled (healthy volunteers and obese) population.
Table 2. Spearman Correlations Between Biomarkers of Inﬂammation, Insulin Resistance, Adiposity, Cardiac Stress, and CMR
Indices for the Entire Population (Obese and Obese/T2D Pooled)
Variable
Inﬂammation Dysglycemia and Insulin Resistance Adiposity
Cardiac Stress and
Fibrosis
hsCRP Serum Triglycerides HOMA-IR Fasting Glucose Hemoglobin A1c Adiponectin Leptin NT-Pro-BNP Gal-3
LVEF 0.18 0.28 0.15 0.03 0.22 0.39 0.08 0.11 0.08
LVESV index 0.17 0.08 0.15 0.29 0.47* 0.19 0.19 0.09 0.04
LVEDV index 0.14 0.07 0.18 0.36 0.45* 0.09 0.25 0.15 0.12
LV mass index 0.42 0.24 0.05 0.23 0.34 0.11 0.17 0.11 0.42
LV mass/volume 0.09 0.13 0.04 0.20 0.12 0.17 0.25 0.01 0.26
LA volume index 0.01 0.15 0.36 0.01 0.03 0.05 0.29 0.13 0.25
Aortic PWV 0.11 0.26 0.10 0.03 0.21 0.39 0.09 0.14 0.16
Myocardial ECV 0.47* 0.51* 0.29 0.29 0.76*** 0.24 0.16 0.09 0.36
Each cell contains the Spearman correlation coefﬁcient between the given CMR index (row) and the biomarker (column). LVESV, LVEDV, LV mass, and LA volume are all indexed to height.
CMR indicates cardiac magnetic resonance imaging; T2D, type 2 diabetes; hsCRP, high-sensitivity C-reactive protein; HOMA-IR, homeostatic model assessment of insulin resistance;
NT-pro-BNP, N-terminal probrain natriuretic peptide; Gal-3, galectin-3; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVEDV, left ventricular
end-diastolic volume; LA, left atrial; PWV, pulse wave velocity; ECV, extracellular volume fraction.
*P<0.05, **P<0.01, ***P<0.005.
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Myocardial Tissue Remodeling Is Associated With
Biomarkers of Systemic Inﬂammation and
Dysglycemia
Spearman correlations between biomarkers of inﬂammation,
insulin resistance, adiposity, cardiac stress, and CMR indices
for obese adolescents are shown in Table 2. Myocardial ECV
was associated with high-sensitivity C-reactive protein
(r=0.47, P<0.05) and serum triglycerides (r=0.51, P<0.05;
Figure 3), both markers of cardiometabolic disease. In
addition, myocardial ECV demonstrated a strong relationship
with dysglycemia (hemoglobin A1c, r=0.76, P<0.0001). More
severe dysglycemia was associated with smaller ventricular
volumes (correlated with hemoglobin A1c). Importantly,
interstitial matrix expansion by myocardial ECV was not
associated with biomarkers of cardiovascular stress (N-ter-
minal pro-BNP or galectin-3), adiponectin, or leptin.
Discussion
The novel ﬁnding of our study is that signiﬁcant alterations in
myocardial tissue phenotypes as measured by cardiac
magnetic resonance imaging occur in obese adolescents
(particularly those with T2D) before the onset of frank LV
hypertrophy or systolic dysfunction. Obese adolescents
demonstrated a signiﬁcantly greater expansion of the myo-
cardial interstitial matrix relative to healthy volunteers (espe-
cially pronounced in those with T2D), and BMI was associated
with myocardial ECV. Furthermore, markers of inﬂammation
and dysglycemia—key components of cardiometabolic dis-
ease in general—were associated with myocardial interstitial
matrix expansion, and T2D and BMI were strongly and
independently associated with extracellular matrix remodel-
ing. Together, these results constitute the ﬁrst observation in
a pediatric obese population of altered myocardial tissue
phenotypes. This shows that adverse tissue remodeling can
manifest early in the course of obesity and diabetes before
overt LV hypertrophy or dysfunction, which may be reinforced
by cardiometabolic mechanisms central to obesity, namely,
inﬂammation and dysglycemia.
Adolescent obesity remains the most important determi-
nant of risk of metabolic syndrome and its attendant
cardiovascular disease in adulthood. Accordingly, there is
signiﬁcant evidence that obesity eventually strongly affects
cardiac structure, function, and vascular stiffness in adoles-
cents. LVH is more frequent in obese adolescents (age, 13 to
19) after adjustment for blood pressure6 and particularly in
Figure 1. Healthy volunteer versus obese diabetic individual. Four
chamber cine-SSFP image in end-diastole and representative
left-ventricular measurements. This obese diabetic adolescent has
left ventricular measures of function and volume similar to the
healthy volunteer; however, the myocardial extracellular volume
fraction is signiﬁcantly higher in the obese diabetic adolescent. SSFP
indicates steady-state free precession; LVEF, left ventricular ejection
fraction; LV mass, left ventricular mass; LVEDV, left ventricular
end-diastolic volume; ECV, extracellular volume fraction.
A
B
Figure 2. A, Myocardial extracellular volume fraction assessment
by CMR stratiﬁed by obesity and diabetic status. The central line
represents the median, and the whiskers represent 1.5 times the
interquartile range. Healthy volunteers had the lowest ECV by CMR,
followed by obese adolescents without T2D. Obese adolescents with
T2D had the highest ECV by CMR. P values for Kruskal–Wallis
comparisons between groups are adjusted for multiple comparisons.
B, Relationship of ECV to body mass index across healthy volunteers
and obese individuals (ﬁtted using a Loess spline), demonstrating a
signiﬁcant association of ECV with BMI. CMR indicates cardiac
magnetic resonance imaging; ECV, extracellular volume fraction; BMI,
body mass index; T2D, type 2 diabetes.
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the presence of metabolic syndrome.26 Obesity is accompa-
nied by increased arterial stiffness,27 diastolic dysfunc-
tion,28,29 and impaired exercise capacity.30 The degree of
diastolic impairment exists on a spectrum from lean to obese
to obese diabetic adolescents, associated with hypertension,
BMI, and dysglycemia.31 Subclinical systolic dysfunction (by
echocardiographic strain) is associated with insulin resistance
and BMI.32 Furthermore, these abnormalities may be revers-
ible (even in the morbidly obese) with surgical weight loss.33
Current imaging modalities identify established dysfunction at
the organ level (eg, diastolic dysfunction, LVH) in obese youth,
when adverse remodeling may be irreversible and unrespon-
sive to potential therapies. Therefore, earlier detection of
myocardial tissue phenotypes that may exist before cardiac
dysfunction or frank LV hypertrophy are critical to disease
prevention and earlier targeted therapy.
Hyperglycemia and insulin resistance have been associ-
ated with subtle alterations in the myocardial interstitium
(myocardial ﬁbrosis, deposition of advanced glycation
end-products) that contribute to diastolic dysfunction.8–11
Studies in animal models of obesity along the spectrum from
insulin resistance to T2D suggest the presence of interstitial
myocardial ﬁbrosis and cardiomyocyte hypertrophy as early
hallmarks of obesity/diabetic cardiomyopathy34–36 before
ventricular dysfunction.34,37 Circulating markers of myocardial
ﬁbrosis and echocardiographic integrated backscatter have
been associated with insulin resistance and diastolic dys-
function in obese adults.38,39
In this work, we provide a comprehensive cardiac pheno-
type, including tissue-level alterations in myocardial extracel-
lular matrix, in obese adolescents. There is a signiﬁcant
stepwise increase in myocardial ECV from normal-weight
healthy volunteers to obese individuals without and with T2D,
which is in agreement with studies demonstrating progressive
worsening of diastolic function with obesity and dysglycemia
status.31 Importantly, these increases in extracellular volume
fraction occur in parallel with changes in LV mass and
volumes but without changes in LV function between obese
adolescents and healthy volunteers, suggesting that ECV may
be a sensitive parameter for detecting early remodeling before
LV hypertrophy or dysfunction. Furthermore, height-indexed
LV mass (a sensitive marker accessible by echocardiography
in adolescents) did not meet published criteria for left
ventricular hypertrophy in any group,25 suggesting that
myocardial remodeling may occur at lesser degrees of
hypertrophy in adolescents. Interestingly, higher ECV was
associated with smaller LV volumes and higher LVEF, even
within a relatively normal range, a phenotype seen in older
individuals with heart failure and preserved systolic function.
Indeed, the presence of T2D and BMI were strong indepen-
dent correlates of ECV, suggesting a central role for
dysglycemia in extracellular matrix expansion. These ﬁndings
are congruent with observations in animal models supporting
a primary role for dysglycemia and insulin resistance in
extracellular matrix expansion in the heart.8–11 Furthermore,
given the clear association between obesity/T2D, ventricular
remodeling, and heart failure in adults,40,41 these ﬁndings
provide a rationale for aggressive preventive strategies earlier
in the life course of obesity (eg, in adolescence) to prevent
incident heart failure.
Figure 3. Inﬂammation and dysglycemia are associated with myocardial tissue remodeling in obese adolescents. Myocardial ECV is associated
with high-sensitivity C-reactive protein and triglycerides (markers of systemic inﬂammation and visceral adiposity), as well as hemoglobin A1c
(marker of dysglycemia). A linear ﬁt using a least-squares (Spearman) correlation was used, utilizing a log-transformed dependent variable
(biomarker). A Loess spline was added to the ﬁgure to illustrate the nonuniform increase of ECV with BMI. The symbol q refers to Spearman’s rank
correlation. ECV indicates extracellular volume fraction; BMI, body mass index.
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In addition, we observed important associations between
serum biomarkers relevant to cardiometabolic disease and
ECV. Although gross cardiac structural and functional param-
eters in the obese population were similar to healthy
volunteers, markers of inﬂammation and glycemic control
were abnormal and associated with extracellular matrix
expansion by CMR. Interestingly, although hemoglobin A1c,
triglycerides, and high-sensitivity C-reactive protein (CRP)
were associated with ECV, selected adipokine implicated in
adult obesity (including leptin and adiponectin) were not
associated with ECV in our population. The role of adiponectin
in myocardial remodeling remains complex, with demonstra-
tion of antiﬁbrotic and inﬂammatory effects in animal models
and conﬂicting relationships between adiponectin, hypertro-
phy, and diastolic function in human heart failure.42–44 In
addition, leptin appears to promote myocardial ﬁbrosis.45 Our
demonstration of an elevated myocardial ECV reﬂecting
extracellular matrix remodeling in adolescents provides the
rationale for future work examining the role of the adipokine
response to obesity. Ultimately, these results suggest that
obesity-mediated cardiometabolic pathways (speciﬁcally dys-
glycemia and inﬂammation) may mediate subclinical myocar-
dial remodeling early in the adolescent obese before overt LV
hypertrophy or dysfunction.
Despite an association between interstitial ﬁbrosis and
myocardial ECV in pressure-overload states,13,46 prior work
using similar T1-based CMR measures in diabetes and
cardiometabolic disease has been limited. Work by Jellis and
colleagues in adults with diabetes without clinical cardiovas-
cular disease demonstrated that a single measurement of
postcontrast T1 was modestly associated with echocardio-
graphic diastolic dysfunction, blood pressure, and insulin
sensitivity, but not with LV mass or circulating markers of
collagen turnover.15. In large community-based populations
without cardiovascular disease, obesity-mediated increases in
LV mass may be mediated by inﬂammation,47 and markers of
proinﬂammatory visceral adiposity and inﬂammation are
associated with obesity-mediated concentric LV remodeling
and heart failure.40,41
Our ﬁnding that myocardial matrix expansion already exists
in obese adolescents (particularly those with T2D) extends
prior observations to a potentially earlier stage of obes-
ity-mediated heart disease. Extracellular matrix expansion is
prevalent in obese adolescents, suggesting obese adolescents
harbor a wide range of subclinical myocardial damage not
detected by standard markers of ventricular structure and
function. Furthermore, the association with markers of
inﬂammation and dysglycemia highlights the interplay
between metabolism and cardiac remodeling in the very early
stages of obesity-related cardiomyopathy. Given the recently
reported association between myocardial ECV and mortality in
adulthood,47 these results ultimately provide the impetus to
larger studies of the effect of early detection and intervention
(with a wider array of antiremodeling, weight loss, and
dysglycemia therapies) in this population to prevent cardiac
remodeling and heart failure.
The results of our study should be viewed in the context of
its design and potential limitations. Despite the limited
number of individuals in our study, we were adequately
powered to detect the differences we observed in myocardial
ECV, and the associations between myocardial ECV, weight,
and cardiometabolic risk markers (eg, CRP and dysglycemia)
remain strong and biologically plausible. Endomyocardial
biopsy to conﬁrm collagen as the etiology of ECV in this
population is impossible to obtain in this preclinical, young
population; however, the prognostic relevance of ECV eleva-
tion in an older cohort has been established, regardless of
cause.47 Indeed, the relationships observed between inﬂam-
mation/insulin resistance and ECV—and the young age of the
individuals studied here—suggest that alternative mecha-
nisms (eg, advanced glycation end-products) and not neces-
sarily myocardial ﬁbrosis may be the origin of elevated ECV.
Although we did not perform echocardiography in these
patients to provide canonical measures of diastolic function,
left atrial volumes (a sensitive marker of chronicity of diastolic
dysfunction) were similar in the obese and healthy population
and were not associated with ECV, suggesting that the obese
adolescents studied here may harbor a very early, preclinical
phenotype before even the onset of signiﬁcant diastolic
dysfunction. Finally, although our population of healthy young
controls (not necessarily postpubertal) was derived from
patients without clinical cardiovascular disease imaged at a
different site from the obese adolescents, the range of
myocardial ECV in this young healthy population was consis-
tent with previous reports of healthy volunteers.48
In conclusion, obesity in adolescents is associated with
extracellular matrix expansion before signiﬁcant ventricular
hypertrophy or dysfunction, particularly in obese adolescents
with T2D. These changes are associated with dysglycemia and
inﬂammation, suggesting mechanistic links between cardio-
metabolic risk and early myocardial tissue phenotypes in
pediatric obesity. Given the public health impact of pediatric
obesity, these results suggest that myocardial tissue-level
remodeling may be present even earlier than previously
described in the obese adolescent and motivate more
aggressive detection and therapy to improve disease preven-
tion. Larger studies to deﬁne the physiologic and biochemical
relevance of novel, tissue-level remodeling and its reversibility
are warranted in this emerging at-risk population.
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